Company Description
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Country | United States |
Founded | 1998 |
IPO Date | Jul 25, 2013 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 17 |
CEO | Dr. Werner Cautreels Ph.D. |
Contact Details
Address: 12 Penns Trail Newtown, Pennsylvania 18940 United States | |
Phone | 267-759-3680 |
Stock Details
Ticker Symbol | TRAW |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001130598 |
ISIN Number | US68232V8019 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Werner Cautreels Ph.D. | Chief Executive Officer and Director |
Dr. Steven M. Fruchtman M.D. | President and Chief Scientific Officer of Oncology |
Mark Patrick Guerin CPA | Chief Financial Officer |
Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | Executive Chairman |
Dr. Nikolay Savchuk Ph.D. | Chief Operating Officer and Director |
Dr. Victor Moyo M.D. | Chief Medical Officer |
Robert Redfield M.D. | Chief Medical Officer |
C. David Pauza Ph.D. | Chief Scientific Officer of Virology |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Jun 28, 2024 | 8-K | Current Report |
Jun 27, 2024 | PRE 14A | Other preliminary proxy statements |
Jun 21, 2024 | 8-K | Current Report |
Jun 17, 2024 | 8-K/A | [Amend] Current report |
May 22, 2024 | 8-K | Current Report |
May 16, 2024 | 8-K | Current Report |
May 15, 2024 | 10-Q | Quarterly Report |
Apr 29, 2024 | 10-K/A | [Amend] Annual report |
Apr 16, 2024 | D | Notice of Exempt Offering of Securities |